drug adverse effects of erythropoiesis-stimulating agents
Jump to navigation
Jump to search
Adverse effects
- chronic kidney disease
- increase in death & cardiovascular events when used to increase hemoglobin above 11 g/dL[3][5]; (initial report 12 g/dL) or history of stroke[5]
- ref[2] does not confirm
- increased risk of thrombosis risk[1][2]
- increased risk of stroke[1][2] HR= 1.51
- increased risk or worsening of hypertension[2]
- probably increases risks for death,cardiovascular events, & end-stage renal disease[2]
- progression of chronic renal failure[4]
- increase in death & cardiovascular events when used to increase hemoglobin above 11 g/dL[3][5]; (initial report 12 g/dL) or history of stroke[5]
- cancer
- erythropoiesis-stimulating agents & cancer are both associated with an increased risk of thrombosis[6]
- may shorten survival & time to tumor progression of some cancers when used in high doses & increase mortality[5]
- may be growth signal
- surgery
- increased risk of deep vein thrombosis after orthopedic surgery in some patients
More general terms
References
- ↑ 1.0 1.1 1.2 Prescriber's Letter 14(6): 2007 Safe Use of Erythropoiesis-Stimulating Agents (ESAs) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230607&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med July 6, 2010; 153(1):53-55. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20439566
- ↑ 3.0 3.1 FDA MedWatch: 06/25/2011 Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm260641.htm
- ↑ 4.0 4.1 Inrig JK et al. Effect of hemoglobin target on progression of kidney disease: A secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012 Sep; 60:390 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22537421
- ↑ 5.0 5.1 5.2 5.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 19 American College of Physicians, Philadelphia 2012, 2015, 2022
- ↑ 6.0 6.1 Bohlius J, Bohlke K, Castelli R et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv 2019 Apr 23; 3:1197 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30971397 Free PMC Article <Internet> http://www.bloodadvances.org/content/3/8/1197